B1Neuro

B1Neuro operates at the intersection of precision psychiatry, neuroimaging, and neuromodulation. Its proposed differentiation is the use of individual-level fMRI brain mapping and network analysis to guide TMS targeting, addressing a limitation of conventional approaches that may rely on standardized anatomical landmarks or less personalized treatment protocols. The company’s focus is narrower than that of broad digital mental-health platforms because its model is centered on clinical brain stimulation and the underlying targeting workflow. It also differs from hardware-led neuromodulation companies by emphasizing the software and imaging layer that determines where stimulation should be applied. Within the broader market, B1Neuro would likely compete for clinical adoption against established TMS systems, precision-neuromodulation developers, and academic or hospital-based neuroimaging protocols. Its potential advantage is the integration of fMRI, machine learning, and treatment delivery into an individual-level workflow. Its main market constraints are not yet resolved publicly: evidence of clinical efficacy, reproducibility across sites, workflow burden, reimbursement, regulatory status, and the cost and availability of MRI-guided treatment. The company’s market position remains early-stage and research-led rather than commercially established.

B1Neuro’s observable trajectory begins with research from NUS’s Computational Brain Imaging Group and its individual-level brain network mapping algorithm, followed by participation in the NUS GRIP programme in November 2024. That progression suggests a transition from academic research toward company formation and translational development, although the available profile does not disclose the incorporation date, employee growth, financing amount, or subsequent capital events. The technical direction is consistent across the company’s materials: fMRI is used to characterize individual brain networks, machine learning supports neurotargeting, and TMS provides the treatment modality. Depression, including treatment-resistant depression, appears to be the initial clinical focus, with possible extension to other psychiatric or neurological conditions. The principal future inflection points would be validation of targeting accuracy, clinical evidence demonstrating better outcomes or efficiency than standard TMS, regulatory progress, and adoption by treatment centers. The November 2024 NUS GRIP milestone provides evidence of early venture development, but the absence of disclosed funding totals, product launches, partnerships, and hiring data limits confidence in the company’s current scale and commercial momentum as of Oct 7, 2026.